Allegra Sales Decline Will Not Prompt OTC Switch, Aventis Says

Decreasing Allegra sales in the face of increased competition from OTC antihistamines will not lead Aventis to pursue a switch for the drug, the firm stated during an Oct. 30 call on third-quarter results